IGF1R and ovarian cancer: A correlation of increasing IGF-1R expression with decreasing sensitivity to cisplatin and paclitaxel was shown across a panel of cell lines representing different subtypes of ovarian cancer, including adenocarcinoma (A2780, A2780Cis, OVCAR8, OVCAR5, PEO14, PEO23, PEA1, PEA2, SKOV3), serous (OVCAR3, OV90, PEO1, PEO4), clear cell (TOV-21G), and endometrioid (TOV-112D) ovarian cancer subtypes, suggesting a broad applicability of this research in this disease indication.